Hard to Treat Diseases Inc. and its China subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and Rubella Combined Vaccine Live) had obtained a 'pass' on its First Drug Evaluation. On November 2, 2009, State Food and Drug Administration held a Drug Evaluation Conference to determine, whether HTDS' MMR vaccine meets the requirements for release onto the Chinese pharmaceutical market. HTDS' experts and representatives from the manufacturer (Serum Institute of India Ltd.) presented the MMR attenuated vaccine to the SFDA's expert panel. The HTDS' MMR vaccine received a 'pass' on its First Drug Evaluation. Based on the research and clinical trial results presented, the panel concurred that the Mellow Hope's MMR vaccine had a good safety profile, therefore, the vaccine will undergo further inquiry for the final SFDA approval. The First Drug Evaluation panel will submit the results for final approval. This approval will secure HTDS the production license for MMR vaccine.

Hard to Treat Diseases Inc. announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored. They revealed that repetitive HBO treatments, which started 1 hour after traumatic brain injury, significantly reduced neuronal loss and degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury. These data indicate that HBO-induced prevention of neurodegeneration might be beneficial in improvement of neurological outcome after traumatic brain injury.

Hard to Treat Diseases Inc. announced that the (H1N1) Vaccine for Mellow Hope Inc. At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration. Production will be started shortly.